Sarah Krepp Sells 4,557 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 4,557 shares of the firm’s stock in a transaction on Monday, April 13th. The stock was sold at an average price of $38.37, for a total value of $174,852.09. Following the completion of the sale, the insider directly owned 147,019 shares of the company’s stock, valued at $5,641,119.03. This represents a 3.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Performance

NASDAQ:LQDA opened at $40.12 on Thursday. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. The business has a fifty day simple moving average of $36.63 and a two-hundred day simple moving average of $33.08. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $46.67. The company has a market capitalization of $3.53 billion, a P/E ratio of -48.34 and a beta of 0.45.

Liquidia (NASDAQ:LQDA) last released its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The business had revenue of $92.02 million during the quarter, compared to the consensus estimate of $87.49 million. The firm’s quarterly revenue was up 3072.4% compared to the same quarter last year. On average, analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on LQDA shares. Raymond James Financial reissued a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Zacks Research downgraded Liquidia from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 27th. BTIG Research lifted their price target on Liquidia from $49.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Wells Fargo & Company lifted their price target on Liquidia from $44.00 to $51.00 and gave the company an “overweight” rating in a research report on Monday, March 23rd. Finally, HC Wainwright lifted their price target on Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $43.44.

Hedge Funds Weigh In On Liquidia

Several hedge funds have recently made changes to their positions in the stock. Covestor Ltd grew its position in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Liquidia by 7.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock valued at $217,000 after buying an additional 422 shares during the period. Whitcomb & Hess Inc. boosted its stake in Liquidia by 2.0% during the third quarter. Whitcomb & Hess Inc. now owns 28,385 shares of the company’s stock valued at $645,000 after buying an additional 558 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in Liquidia during the fourth quarter valued at $25,000. Finally, ProShare Advisors LLC boosted its stake in Liquidia by 7.1% during the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after buying an additional 775 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported an earnings beat for the quarter ended Mar 5 (revenue and EPS above consensus), which supports near‑term fundamentals and helps justify analyst upside. Read More.
• Positive Sentiment: Several brokers have reiterated or raised bullish views and price targets (multiple buy / strong‑buy ratings and target upgrades), providing analyst support for the stock’s rally. Read More.
• Neutral Sentiment: Institutional ownership is substantial (~64.5%), and some funds have added modest positions recently — this can mute volatility from insider selling if institutions hold. Read More.
• Negative Sentiment: Broad insider selling: multiple insiders (CEO Roger Jeffs, CFO Michael Kaseta, General Counsel Russell Schundler, CAO Dana Boyle and others) disclosed sales between Apr 9–13. Many filings say the trades were under 10b5‑1 plans and to cover tax withholding on vested awards, but the pattern can still weigh on sentiment near recent highs. Read More.
• Negative Sentiment: Notable large block: CFO Michael Kaseta disclosed a 133,789‑share sale (reported earlier in filings), a materially sizeable reduction that may attract extra scrutiny about insider conviction despite stated tax/10b5‑1 reasons. Read More.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).